# Trade Mark Journal No.2026/031 31 July 2026

## WO0000001927781 (1,5,42)

Office of origin: United States of America

Date of International Registration:15 June 2026
Date of designation in the UK: 15 June 2026

International priority date claimed: 18 December 2025 (United States of America) (99555226)

Class 1
  Active chemical ingredients for use in the manufacture of pharmaceuticals for treating neurological conditions and diseases.
Class 5
  Pharmaceutical preparations for the treatment of neurological conditions and diseases.
Class 42
  Pharmaceutical research and development.

Montara Therapeutics, Inc.

Representative: Michael R. Graif Brown Rudnick LLP, 7 Times Square, New York NY 10036, UNITED STATES OF AMERICA